论文部分内容阅读
目的:探讨参麦注射液用于治疗慢性呼吸衰竭急性加重患者的临床效果。方法:选取2011年3月-2012年6月在我愿接受治疗的慢性呼吸衰竭急性加重的患者68例,随机分为参麦组和对照组,每组各34例。对照组采取常规方法进行治疗,参麦组在此基础上给予参麦注射液加以治疗。观察并比较两组患者的治愈率、住院时间、肺功能指标(FEV1)及血气分析情况等相关指标。结果:参麦组的治愈率为91.18%,与对照组的53.12%相比较,差异显著(X2=10.8800,P<0.05)。参麦组的住院时间显著短于对照组,其肺功能指标、血气分析结果包括氧分压值和二氧化碳分压值均明显优于对照组,具有统计学意义(P<0.05)。结论:参麦注射液治疗慢性呼吸衰竭急性加重疾病不失为一种优良的治疗方案,不仅患者临床症状得到明显的改善,病情好转加快,还可以调节患者的免疫力,在临床上值得推广。
Objective: To investigate the clinical effect of Shenmai injection in the treatment of acute exacerbation of chronic respiratory failure. Methods: From March 2011 to June 2012, 68 patients with acute exacerbation of chronic respiratory failure who were willing to receive treatment were randomly divided into Shenmai group and control group, with 34 cases in each group. Control group to take the conventional method of treatment, Shenmai group on the basis of Shenmai injection to be treated. The cure rate, length of hospital stay, pulmonary function index (FEV1), blood gas analysis and other related indicators were observed and compared between the two groups. Results: The cure rate of Shenmai group was 91.18%, which was significantly different from that of the control group (53.12%) (X2 = 10.8800, P <0.05). Shenmai hospitalization time was significantly shorter than the control group, the pulmonary function indicators, blood gas analysis results, including oxygen partial pressure and partial pressure of carbon dioxide values were significantly better than the control group, with statistical significance (P <0.05). Conclusion: Shenmai injection in the treatment of acute exacerbation of chronic respiratory failure is an excellent treatment. Not only the clinical symptoms of patients have been significantly improved, the condition improved faster, but also can adjust the patient’s immune system, which is worthy of clinical promotion.